LRP与c-erbB-2在上皮性卵巢癌中的表达及临床意义

The expression of lung resistance protein and c-erbB-2 in primary epithelial ovarian cancer and its clinical significance

目的探讨肺耐药蛋白(lungresistanceprotein,LRP)与c-erbB-2在上皮性卵巢癌中的表达及其临床意义。方法采用免疫组织化学SP法检测108例上皮性卵巢癌组织和10例正常卵巢组织中LRP和c-erbB-2的表达,并进行相关的临床病理参数分析。结果LRP和c-erbB-2在上皮性卵巢癌中的阳性表达率分别为70.4%和64.8%,而正常卵巢组织中均未见表达,两者表达差异均有显著性(P<0.05)。上皮性卵巢癌组织中LRP的表达与上皮性卵巢癌组织学类型、临床分期、病理分级、患者年龄、残留病灶等临床病理参数无关。c-erbB-2的表达与组织学类型、临床分期、患者年龄和残留病灶无关,与病理分级有关(P<0.05)。LRP表达阳性的卵巢癌患者对化疗的反应率(44.7%)明显低于LRP表达阴性者(93.7%)(P<0.05);c-erbB-2表达阳性的卵巢癌患者对化疗的反应率(42.8%)明显低于c-erbB-2表达阴性者(89.4%)(P<0.05)。结论LRP和c-erbB-2在上皮性卵巢癌中有较恒定的表达,且阳性表达预示化疗反应率低,可能成为预测卵巢癌化疗耐药的指标。

Objective： To investigate the expression of lung resistance protein and c - erbB - 2 in epithelial ovarian cancer tissues and its clinical significance. Methods： The expression of LRP and c - erbB - 2 in paraffin embedded 108 cases of epithelial ovarian cancer tissues and 10 normal ovarian tissues were determined by SP immunohistochemical methods . Results： The positive rates of LRP and c - erbB - 2 in epithelial ovarian cancer were 70.4% and 64.8% respectively. While the expression of LRP and c - erbB - 2 was not found in normal ovarian tissues. There was significant difference （P 〈 0.05 ）. The expression of LRP was not associated with histologic type, FIGO stage, grade, age and residual disease in epithelial ovarian cancer. The expression of c - erbB - 2 was not associated with histologic type, FIGO stage, age and residual disease, but was associated with grade （P 〈 0.05 ）. The response rates to chemotherapy in patients with LRP positive and LRP negative were 44.7% and 93.7% respectively （ P 〈0.05）. While the response rates to chemotherapy in patients with c -erbB -2 positive and c -erbB -2 negative were 42.8% and 89.4% respectively （P 〈 0.05 ）. Conclusions： The expression of LRP and c - erbB - 2 in epithelial ovarian cancer is more frequently observed and related with drug resistance, and may be a predictable marker of chemotherapy in epithelial ovarian cancer.